StreetInsider.com News Articles

FDA Commissioner Marty Makary to step down - Politico

Tue, 12 May 2026 12:53:53 -0400

(Updated - May 12, 2026 12:53 PM EDT)

FDA Commissioner Marty Makary to step down - Politico

After a turbulent 13-month tenure, gastrointestinal surgeon Marty Makary is resigning as FDA commissioner effective Tuesday, according to reporting from Politico.
Kyle Diamantas will take over as acting commissioner following a period defined by significant internal turnover, mass layoffs, and intense policy disputes.

FDA Commissioner Marty Makary to step down - Politico

Tue, 12 May 2026 12:53:53 -0400

(Updated - May 12, 2026 12:53 PM EDT)

FDA Commissioner Marty Makary to step down - Politico

After a turbulent 13-month tenure, gastrointestinal surgeon Marty Makary is resigning as FDA commissioner effective Tuesday, according to reporting from Politico.
Kyle Diamantas will take over as acting commissioner following a period defined by significant internal turnover, mass layoffs, and intense policy disputes.

FDA Commissioner Marty Makary to step down - Politico

Tue, 12 May 2026 12:53:53 -0400

(Updated - May 12, 2026 12:53 PM EDT)

FDA Commissioner Marty Makary to step down - Politico

After a turbulent 13-month tenure, gastrointestinal surgeon Marty Makary is resigning as FDA commissioner effective Tuesday, according to reporting from Politico.
Kyle Diamantas will take over as acting commissioner following a period defined by significant internal turnover, mass layoffs, and intense policy disputes.

FDA Commissioner Marty Makary to step down - Politico

Tue, 12 May 2026 12:53:53 -0400

(Updated - May 12, 2026 12:53 PM EDT)

FDA Commissioner Marty Makary to step down - Politico

After a turbulent 13-month tenure, gastrointestinal surgeon Marty Makary is resigning as FDA commissioner effective Tuesday, according to reporting from Politico.
Kyle Diamantas will take over as acting commissioner following a period defined by significant internal turnover, mass layoffs, and intense policy disputes.

FDA Commissioner Marty Makary to step down - Politico

Tue, 12 May 2026 12:53:53 -0400

(Updated - May 12, 2026 12:53 PM EDT)

FDA Commissioner Marty Makary to step down - Politico

After a turbulent 13-month tenure, gastrointestinal surgeon Marty Makary is resigning as FDA commissioner effective Tuesday, according to reporting from Politico.
Kyle Diamantas will take over as acting commissioner following a period defined by significant internal turnover, mass layoffs, and intense policy disputes.

FDA Commissioner Marty Makary to step down - Politico

Tue, 12 May 2026 12:53:53 -0400

(Updated - May 12, 2026 12:53 PM EDT)

FDA Commissioner Marty Makary to step down - Politico

After a turbulent 13-month tenure, gastrointestinal surgeon Marty Makary is resigning as FDA commissioner effective Tuesday, according to reporting from Politico.
Kyle Diamantas will take over as acting commissioner following a period defined by significant internal turnover, mass layoffs, and intense policy disputes.

FDA Commissioner Marty Makary to step down - Politico

Tue, 12 May 2026 12:53:53 -0400

(Updated - May 12, 2026 12:53 PM EDT)

FDA Commissioner Marty Makary to step down - Politico

After a turbulent 13-month tenure, gastrointestinal surgeon Marty Makary is resigning as FDA commissioner effective Tuesday, according to reporting from Politico.
Kyle Diamantas will take over as acting commissioner following a period defined by significant internal turnover, mass layoffs, and intense policy disputes.

FDA Commissioner Marty Makary to step down - Politico

Tue, 12 May 2026 12:53:53 -0400

(Updated - May 12, 2026 12:53 PM EDT)

FDA Commissioner Marty Makary to step down - Politico

After a turbulent 13-month tenure, gastrointestinal surgeon Marty Makary is resigning as FDA commissioner effective Tuesday, according to reporting from Politico.
Kyle Diamantas will take over as acting commissioner following a period defined by significant internal turnover, mass layoffs, and intense policy disputes.

FDA Commissioner Marty Makary to step down - Politico

Tue, 12 May 2026 12:53:53 -0400

(Updated - May 12, 2026 12:53 PM EDT)

FDA Commissioner Marty Makary to step down - Politico

After a turbulent 13-month tenure, gastrointestinal surgeon Marty Makary is resigning as FDA commissioner effective Tuesday, according to reporting from Politico.
Kyle Diamantas will take over as acting commissioner following a period defined by significant internal turnover, mass layoffs, and intense policy disputes.

FDA Commissioner Marty Makary to step down - Politico

Tue, 12 May 2026 12:53:53 -0400

(Updated - May 12, 2026 12:53 PM EDT)

FDA Commissioner Marty Makary to step down - Politico

After a turbulent 13-month tenure, gastrointestinal surgeon Marty Makary is resigning as FDA commissioner effective Tuesday, according to reporting from Politico.
Kyle Diamantas will take over as acting commissioner following a period defined by significant internal turnover, mass layoffs, and intense policy disputes.

FDA Commissioner Marty Makary to step down - Politico

Tue, 12 May 2026 12:53:53 -0400

(Updated - May 12, 2026 12:53 PM EDT)

FDA Commissioner Marty Makary to step down - Politico

After a turbulent 13-month tenure, gastrointestinal surgeon Marty Makary is resigning as FDA commissioner effective Tuesday, according to reporting from Politico.
Kyle Diamantas will take over as acting commissioner following a period defined by significant internal turnover, mass layoffs, and intense policy disputes.

FDA Commissioner Marty Makary to step down - Politico

Tue, 12 May 2026 12:53:53 -0400

(Updated - May 12, 2026 12:53 PM EDT)

FDA Commissioner Marty Makary to step down - Politico

After a turbulent 13-month tenure, gastrointestinal surgeon Marty Makary is resigning as FDA commissioner effective Tuesday, according to reporting from Politico.
Kyle Diamantas will take over as acting commissioner following a period defined by significant internal turnover, mass layoffs, and intense policy disputes.

Biotech funds see $1.5 billion outflows in latest week says Raymond James

Thu, 07 May 2026 15:04:10 -0400

Investing.com -- Healthcare and biotech-focused mutual funds and ETFs recorded net outflows of $1.5 billion for the week ending Wednesday, according to data from Raymond James.

The outflows represented a 1.53% decrease in assets across 130 funds managing approximately $99.5 billion. Year-to-date net outflows have reached $1.98 billion.

This marks the second consecutive week of outflows from the sector.

The breadth ratio, which measures the number of funds experiencing inflows divided by those seeing outflows, increased to 0.48 from 0.45 the previous week.

Raymond James noted that when the breadth ratio reaches 0.3, the biotech sector has historically rallied by an average of 17.5%

Biotech funds see $1.5 billion outflows in latest week says Raymond James

Thu, 07 May 2026 15:04:10 -0400

Investing.com -- Healthcare and biotech-focused mutual funds and ETFs recorded net outflows of $1.5 billion for the week ending Wednesday, according to data from Raymond James.

The outflows represented a 1.53% decrease in assets across 130 funds managing approximately $99.5 billion. Year-to-date net outflows have reached $1.98 billion.

This marks the second consecutive week of outflows from the sector.

The breadth ratio, which measures the number of funds experiencing inflows divided by those seeing outflows, increased to 0.48 from 0.45 the previous week.

Raymond James noted that when the breadth ratio reaches 0.3, the biotech sector has historically rallied by an average of 17.5%

iShares Nasdaq Biotechnology (IBB) call put ratio 1.3 calls to 1 put into the annual J.P. Morgan Healthcare Conference

Thu, 08 Jan 2026 11:10:08 -0400

iShares Nasdaq Biotechnology (NASDAQ: IBB) 30-day option implied volatility is at 21; compared to its 52-week range of 17 to 46. Call put ratio 1.3 calls to 1 put into the annual J.P. Morgan Healthcare Conference.

Buy this biotech stock ahead of underdog commercial launch

Fri, 17 Oct 2025 08:00:00 -0400

Bank of America, in a Thursday note, flagged a “rare (disease) opportunity,” as it initiated coverage on a biotech stock it believes is set up for an underappreciated commercial launch.

While the broader sector has seen sharp swings this year, the upcoming catalysts tied to a novel autoimmune therapy create a setup that could unlock substantial equity upside.

The bank is referring to Vera Therapeutics (NASDAQ: VERA), whose lead drug atacicept targets IgA nephropathy, a rare kidney disorder with a peak market opportunity estimated at around $15 billion.

BofA started coverage on the stock with a Buy rating and a $48 price objective,

Buy this biotech stock ahead of underdog commercial launch

Fri, 17 Oct 2025 08:00:00 -0400

Bank of America, in a Thursday note, flagged a “rare (disease) opportunity,” as it initiated coverage on a biotech stock it believes is set up for an underappreciated commercial launch.

While the broader sector has seen sharp swings this year, the upcoming catalysts tied to a novel autoimmune therapy create a setup that could unlock substantial equity upside.

The bank is referring to Vera Therapeutics (NASDAQ: VERA), whose lead drug atacicept targets IgA nephropathy, a rare kidney disorder with a peak market opportunity estimated at around $15 billion.

BofA started coverage on the stock with a Buy rating and a $48 price objective,

Buy this biotech stock ahead of underdog commercial launch

Fri, 17 Oct 2025 08:00:00 -0400

Bank of America, in a Thursday note, flagged a “rare (disease) opportunity,” as it initiated coverage on a biotech stock it believes is set up for an underappreciated commercial launch.

While the broader sector has seen sharp swings this year, the upcoming catalysts tied to a novel autoimmune therapy create a setup that could unlock substantial equity upside.

The bank is referring to Vera Therapeutics (NASDAQ: VERA), whose lead drug atacicept targets IgA nephropathy, a rare kidney disorder with a peak market opportunity estimated at around $15 billion.

BofA started coverage on the stock with a Buy rating and a $48 price objective,

Buy this biotech stock ahead of underdog commercial launch

Fri, 17 Oct 2025 08:00:00 -0400

Bank of America, in a Thursday note, flagged a “rare (disease) opportunity,” as it initiated coverage on a biotech stock it believes is set up for an underappreciated commercial launch.

While the broader sector has seen sharp swings this year, the upcoming catalysts tied to a novel autoimmune therapy create a setup that could unlock substantial equity upside.

The bank is referring to Vera Therapeutics (NASDAQ: VERA), whose lead drug atacicept targets IgA nephropathy, a rare kidney disorder with a peak market opportunity estimated at around $15 billion.

BofA started coverage on the stock with a Buy rating and a $48 price objective,

iShares Nasdaq Biotechnology (IBB) 30-day option implied volatility as share price up

Thu, 02 Oct 2025 04:43:18 -0400

iShares Nasdaq Biotechnology (NASDAQ: IBB) 30-day option implied volatility is at 22; compared to its 52-week range of 16 to 46 as share price up.

iShares Nasdaq Biotechnology (IBB) 30-day option implied volatility low, share price up 2.2%

Wed, 01 Oct 2025 10:22:32 -0400

iShares Nasdaq Biotechnology (NASDAQ: IBB) 30-day option implied volatility is at 20; compared to its 52-week range of 16 to 46 as share price up 2.2%.

iShares Nasdaq Biotechnology (IBB) call put ratio 1 call to 1.7 puts

Tue, 08 Jul 2025 03:02:38 -0400

iShares Nasdaq Biotechnology (NASDAQ: IBB) 30-day option implied volatility is at 22; compared to its 52-week range of 16 to 46. Call put ratio 1 call to 1.7 puts.

Pharma stocks recover from initial shock of Trump's drug pricing order

Mon, 12 May 2025 07:15:46 -0400

By Sriparna Roy and Joel Jose

(Reuters) -Shares of U.S. drugmakers rebounded on Monday after an initial selloff as analysts said that President Donald Trump's sweeping executive order to slash prescription drug prices would be difficult to implement and face legal challenges.

Trump signed a wide-reaching executive order on Monday directing drugmakers to lower the prices of

Pharma stocks recover from initial shock of Trump's drug pricing order

Mon, 12 May 2025 07:15:46 -0400

By Sriparna Roy and Joel Jose

Trump signed a wide-reaching executive order on Monday directing drugmakers to lower the prices of

Exclusive-US pharma tariffs would raise US drug costs by $51 billion annually, report finds

Fri, 25 Apr 2025 09:53:01 -0400

By Maggie Fick

LONDON (Reuters) -A 25% U.S. tariff on pharmaceutical imports would increase U.S. drug costs by nearly $51 billion annually, boosting U.S. prices by as much as 12.9% if passed on, a report commissioned by the industry's U.S. trade group and reviewed by Reuters shows.

The analysis, conducted by Ernst & Young, found the United States imported $203